(Reuters) – Swiss pharmaceutical company Roche is considering divesting cancer data specialist Flatiron Health, the Financial Times reported on Wednesday, citing people familiar with the matter.
Roche had paid $1.9 billion for New-York based Flatiron Health in 2018.
https://i-invdn-com.investing.com/news/LYNXNPEB6J0AJ_L.jpg
Source link
Reuters
